Pfizer, Valneva's Lyme Disease Vaccine Application Validated By EMA
(RTTNews) - Pfizer Inc. (PFE) and Valneva SE (VALN) said Friday that the European Medicines Agency (EMA) has validated their Marketing Authorization Application for PF-07307405, a Lyme disease vaccine candidate, allowing the regulator to begin its assessment.
The application is supported by efficacy of more than 70% in the Phase 3 VALOR trial, which evaluated whether PF-07307405 could prevent Lyme disease in individuals aged five years and older. The vaccine was well tolerated, with no safety concerns identified during the trial.
Valneva shares rose nearly 13% in after-hours trading after closing at $5.65 on Thursday, while Pfizer shares gained 1.86% to close at $26.80.
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.